Shanghai Pharmaceuticals: Diprophylline Injection Passes Generic Consistency Evaluation.

Shanghai Pharmaceuticals announced that recently, its subsidiary Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for its hydroxypropyl theophylline injection. The drug has passed the consistency evaluation of generic drug quality and efficacy. Hydroxypropyl theophylline injection is used to relieve symptoms of asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and can also be used for asthma caused by cardiogenic pulmonary edema. The amount of hydroxypropyl theophylline injection purchased by mainland China hospitals in 2024 is RMB 9.737 million.